CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer

Breast Cancer Research and Treatment

Volumn 150, Issue 3, 2015, Pages 559-567

  Conley, Sarah J ^a   Baker, Trenton L ^a   Burnett, Joseph P ^a   Theisen, Rebecca L ^a   Lazarus, Douglas ^b   Peters, Christian G ^b   Clouthier, Shawn G ^a   Eliasof, Scott ^b   Wicha, Max S ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b Cerulean Pharma Inc   (United States)

Author keywords

Antiangiogenic; Camptothecin; Cancer stem cell; CRLX101; HIF 1 ; Hypoxia

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAMPTOTHECIN; CRLX 101; DNA TOPOISOMERASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; CYCLODEXTRIN; IT-101;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; BIOACCUMULATION; BREAST CANCER; CANCER INHIBITION; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESISTANCE; CANCER STEM CELL; CELL COUNT; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; TARGET CELL; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; FEMALE; HUMAN; MAMMARY NEOPLASMS, EXPERIMENTAL; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CAMPTOTHECIN; CELL LINE, TUMOR; CYCLODEXTRINS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MAMMARY NEOPLASMS, EXPERIMENTAL; MCF-7 CELLS; MICE; NEOPLASTIC STEM CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84926205960     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3349-8     Document Type: Article

References (28)

1. Folkman J (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6(4):273–286. doi:10.1038/nrd2115
2. Mackey JR, Kerbel RS, Gelmon KA, McLeod DM, Chia SK, Rayson D, Verma S, Collins LL, Paterson AH, Robidoux A, Pritchard KI (2012) Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials. Cancer Treat Rev. doi:10.1016/j.ctrv.2011.12.002
3. Rose S (2011) FDA pulls approval for avastin in breast cancer. Cancer Discov 1 (7):OF1–2. doi:10.1158/2159-8290.cd-nd112311ol-08
4. Hayes DF (2011) Bevacizumab treatment for solid tumors: boon or bust? JAMA 305(5):506–508. doi:10.1001/jama.2011.57
5. Rapisarda A, Melillo G (2012) Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat Rev Clin Oncol 9(7):378–390. doi:10.1038/nrclinonc.2012.64
6. Wilson WR, Hay MP (2011) Targeting hypoxia in cancer therapy. Nat Rev Cancer 11(6):393–410. doi:10.1038/nrc3064
7. Hill RP, Marie-Egyptienne DT, Hedley DW (2009) Cancer stem cells, hypoxia and metastasis. Semin Radiat Oncol 19(2):106–111. doi:10.1016/j.semradonc.2008.12.002
8. Koch U, Krause M, Baumann M (2010) Cancer stem cells at the crossroads of current cancer therapy failures–radiation oncology perspective. Semin Cancer Biol 20(2):116–124. doi:10.1016/j.semcancer.2010.02.003
9. Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN, Clouthier SG, Wicha MS (2012) Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci USA 109(8):2784–2789. doi:10.1073/pnas.1018866109
10. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, Sim GA (1966) Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and tumor inhibitor from Camptotheca acuminata1,2. J Am Chem Soc 88(16):3888–3890
11. Rapisarda A, Uranchimeg B, Scudiero DA, Selby M, Sausville EA, Shoemaker RH, Melillo G (2002) Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 62(15):4316–4324
12. Rapisarda A, Zalek J, Hollingshead M, Braunschweig T, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Hewitt SM, Shoemaker RH, Melillo G (2004) Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res 64(19):6845–6848. doi:10.1158/0008-5472.can-04-2116
13. Kehrer DF, Soepenberg O, Loos WJ, Verweij J, Sparreboom A (2001) Modulation of camptothecin analogs in the treatment of cancer: a review. Anticancer Drugs 12(2):89–105
14. Svenson S, Wolfgang M, Hwang J, Ryan J, Eliasof S (2011) Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101. J Control Release 153(1):49–55. doi:10.1016/j.jconrel.2011.03.007
15. Eliasof S, Lazarus D, Peters CG, Case RI, Cole RO, Hwang J, Schluep T, Chao J, Lin J, Yen Y, Han H, Wiley DT, Zuckerman JE, Davis ME (2013) Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle. Proc Natl Acad Sci USA 110(37):15127–15132. doi:10.1073/pnas.1309566110
16. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, DeVries S, Lapuk A, Wang NJ, Kuo WL, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, McCormick F, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10(6):515–527. doi:10.1016/j.ccr.2006.10.008
17. Hu Y, Smyth GK (2009) ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 347(1–2):70–78. doi:10.1016/j.jim.2009.06.008
18. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5):555–567. doi:10.1016/j.stem.2007.08.014
19. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, Bertucci F, Stassi G, Dontu G, Birnbaum D, Wicha MS (2009) Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 69(4):1302–1313. doi:10.1158/0008-5472.can-08-2741
20. Puppo M, Battaglia F, Ottaviano C, Delfino S, Ribatti D, Varesio L, Bosco MC (2008) Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha. Mol Cancer Ther 7(7):1974–1984. doi:10.1158/1535-7163.mct-07-2059
21. Rapisarda A, Uranchimeg B, Sordet O, Pommier Y, Shoemaker RH, Melillo G (2004) Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res 64(4):1475–1482
22. Burkitt K, Chun SY, Dang DT, Dang LH (2009) Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment. Mol Cancer Ther 8(5):1148–1156. doi:10.1158/1535-7163.mct-08-0944
23. Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Gehrs B, Raffeld M, Kinders RJ, Parchment R, Anver MR, Shoemaker RH, Melillo G (2009) Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther 8(7):1867–1877. doi:10.1158/1535-7163.mct-09-0274
24. Merritt WM, Nick AM, Carroll AR, Lu C, Matsuo K, Dumble M, Jennings N, Zhang S, Lin YG, Spannuth WA, Kamat AA, Stone RL, Shahzad MM, Coleman RL, Kumar R, Sood AK (2010) Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Mol Cancer Ther 9(4):985–995. doi:10.1158/1535-7163.mct-09-0967
25. Hashimoto K, Man S, Xu P, Cruz-Munoz W, Tang T, Kumar R, Kerbel RS (2010) Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol Cancer Ther 9(4):996–1006. doi:10.1158/1535-7163.mct-09-0960
26. Pham E, Birrer MJ, Eliasof S, Garmey EG, Lazarus D, Lee CR, Man S, Matulonis UA, Peters CG, Xu P, Krasner C, Kerbel RS (2014) Translational Impact of Nanoparticle-Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer. Clin Cancer Res. doi:10.1158/1078-0432.ccr-14-2810
27. Samanta D, Gilkes DM, Chaturvedi P, Xiang L, Semenza GL (2014) Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells. Proc Natl Acad Sci USA. doi:10.1073/pnas.1421438111
28. Keefe SM, Hennessey M, Robinson J, Mykulowicz K, Gunnarsson O, Mamtani R, Vaughn DJ, Hoffman-Censits JH, Nathanson KL, Pryma DA, Eliasof S, Garmey EG, Cohen RB, Haas NB (2014) HIF inhibition in mRCC: Planned interim analysis of CRLX101 with bevacizumab (bev), a phase 1b/2a. ASCO Meeting Abstracts 32 (15_suppl):e15611